Jazz Pharmaceuticals (JAZZ) Non-Current Deffered Revenue (2010 - 2022)
Jazz Pharmaceuticals' quarterly Non-Current Deffered Revenue came in at $116000.0 in Q3 2022, down 88.24% year-on-year from $986000.0 in Q3 2021, and down 49.78% quarter-over-quarter from $231000.0 in Q2 2022.
Jazz Pharmaceuticals has reported Non-Current Deffered Revenue for 13 years, with the latest figure at $116000.0 in Q3 2022.
- For the quarter ending Q3 2022, Non-Current Deffered Revenue fell 88.24% year-over-year to $116000.0; the trailing twelve-month figure through Sep 2022 stood at $116000.0 (down 88.24% YoY), and the FY2021 full-year result was $463000.0, down 80.0% from the prior year.
- Non-Current Deffered Revenue for Q3 2022 stood at $116000.0, down from $231000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $13.6 million in Q1 2018, with the low at $116000.0 in Q3 2022.
- Average Non-Current Deffered Revenue over 5 years is $4.8 million, with a median of $3.6 million recorded in 2020.
- Year-over-year, Non-Current Deffered Revenue sank 38.41% in 2019 and tumbled 88.24% in 2022.
- Tracing JAZZ's Non-Current Deffered Revenue over 5 years: stood at $9.6 million in 2018, then tumbled by 49.26% to $4.9 million in 2019, then tumbled by 52.38% to $2.3 million in 2020, then tumbled by 80.0% to $463000.0 in 2021, then tumbled by 74.95% to $116000.0 in 2022.
- The last three Non-Current Deffered Revenue figures came in at $116000.0 (Q3 2022), $231000.0 (Q2 2022), and $347000.0 (Q1 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Jazz Pharmaceuticals | 14.64 Bn | 12.79 Bn | 934.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 116,000.00 |
| Jun 30, 2022 | 231,000.00 |
| Mar 31, 2022 | 347,000.00 |
| Dec 31, 2021 | 463,000.00 |
| Sep 30, 2021 | 986,000.00 |
| Jun 30, 2021 | 1.51 Mn |
| Mar 31, 2021 | 1.85 Mn |
| Dec 31, 2020 | 2.32 Mn |
| Sep 30, 2020 | 2.95 Mn |
| Jun 30, 2020 | 3.59 Mn |
| Mar 31, 2020 | 4.23 Mn |
| Dec 31, 2019 | 4.86 Mn |
| Sep 30, 2019 | 6.04 Mn |
| Jun 30, 2019 | 7.22 Mn |
| Mar 31, 2019 | 8.40 Mn |
| Dec 31, 2018 | 9.58 Mn |
| Sep 30, 2018 | 10.93 Mn |
| Jun 30, 2018 | 12.29 Mn |
| Mar 31, 2018 | 13.64 Mn |
| Dec 31, 2017 | 16.12 Mn |
| Sep 30, 2017 | 18.27 Mn |
| Jun 30, 2017 | 20.47 Mn |
| Mar 31, 2017 | 22.62 Mn |
| Dec 31, 2016 | 2.60 Mn |
| Sep 30, 2016 | 2.88 Mn |
| Jun 30, 2016 | 3.16 Mn |
| Mar 31, 2016 | 3.44 Mn |
| Dec 31, 2015 | 3.72 Mn |
| Sep 30, 2015 | 3.65 Mn |
| Jun 30, 2015 | 3.93 Mn |
| Mar 31, 2015 | 4.22 Mn |
| Dec 31, 2014 | 4.50 Mn |
| Sep 30, 2014 | 4.78 Mn |
| Jun 30, 2014 | 5.15 Mn |
| Mar 31, 2014 | 5.43 Mn |
| Dec 31, 2013 | 5.72 Mn |
| Sep 30, 2013 | 6.00 Mn |
| Jun 30, 2013 | 6.28 Mn |
| Mar 31, 2013 | 6.57 Mn |
| Dec 31, 2012 | 6.78 Mn |
| Sep 30, 2012 | 7.13 Mn |
| Jun 30, 2012 | 7.36 Mn |
| Mar 31, 2012 | 7.63 Mn |
| Dec 31, 2011 | 7.92 Mn |
| Sep 30, 2011 | 8.20 Mn |
| Jun 30, 2011 | 12,000.00 |
| Dec 31, 2010 | 9.05 Mn |